Posted by Michael Wonder on 27 May 2026
Pfizer's Braftovi becomes first Pfizer therapy to receive priority access under Ontario's FAST program, accelerating treatment for Canadians with metastatic colorectal cancer
26 May 2026 - Pfizer Canada announces that Braftovi (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments (FAST) program.
Following positive reimbursement recommendation from the Canadian Drug Agency, Ontario is the first province to fund Braftovi for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by a validated test.
